{"id":"mrg004a-plus-best-supportive-care","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MRG004A functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming immune evasion mechanisms in cancer. By engaging dual checkpoint targets, the drug aims to synergistically enhance T cell activation and proliferation while reducing immunosuppression in the tumor microenvironment. This approach is intended to improve clinical outcomes when combined with supportive care in advanced malignancies.","oneSentence":"MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:14.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 indication under investigation)"}]},"trialDetails":[{"nctId":"NCT07138846","phase":"PHASE3","title":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2026-01","conditions":"Advanced Pancreatic Cancer","enrollment":231}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MRG004A plus best supportive care","genericName":"MRG004A plus best supportive care","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced or metastatic solid tumors (Phase 3 indication under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}